Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

1

Dyslipidemia significantly increases cardiovascular disease risk, affecting over 523 million people globally.
2

PCSK9 inhibitors (PCSK9i) may help patients achieve LDL targets when statins are ineffective or poorly tolerated.
3

This study evaluates the cost-effectiveness of PCSK9i for secondary stroke prevention in patients with severe intracranial atherosclerosis.
4

A decision-analytic Markov model was used to estimate costs and quality-adjusted life-years (QALYs) over a 5-year horizon.
5

The analysis aims to provide insights into the economic viability of PCSK9i therapy in preventing recurrent strokes.

Jama Network Open

by Caroline Kellogg, Elena Badillo Goicoechea, David D. Kim, Shadi Yaghi, Seemant Chaturvedi, Rachel Mehendale, Karen Orjuela, Tareq Kass-Hout, Rami Z. Morsi, Jacqueline Morales, Eesha Singh, Aditya Jhaveri, Shyam Prabhakaran, Matthew M. Smith, James R. Brorson, Samiksha Golani, Sofia Mazuera, Rachael Kang, Ali Eltatawy, Jessica Pillajo, James E. Siegler
May 5, 2026

1